References
- High Level Pharmaceutical Forum 2005–2008 Final Report. Final conclusions and recommendations of the pharmaceutical forum. Available from: http://www.anm.ro/_/Final%20Conclusions%20and%20Recommendations%20of%20the%20High%20Level%20Pharmaceutical%20Forum.pdf [cited 2 October 2008].
- European Medicines Agency. EUnetHTA. EMA-EUnetHTA three-year work plan: 2013–2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/11/WC500154588.pdf [cited 27 January 2014].
- European Medicines Agency. Summary of opinion (initial authorisation): Tecfidera. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002601/WC500140695.pdf [cited 27 January 2014].
- MULLINDE. Fumaderm – how many UK users are there? [Online forum comment]. Available from: http://www.psoriasis-help.org.uk/forum/psoriasis-discussion-board-the-recreation-room/fumaderm-how-many-uk-users-are-there/ [cited 8 February 2011].
- NIHR Horizon Scanning Centre. Dimethyl fumarate for plaque psoriasis. Skin disease, burns and wound care. Available from: http://www.hsc.nihr.ac.uk/files/downloads/2228/2526.163fbff8.Dimethylfumarate_Nov13.pdf [cited 6 December 2013].
- German DIMDI. Available from: http://www.dimdi.de [cited 17 January 2014].
- Dimethylfumaraat Psorinovo tabletten MSR MVA 30 mg MH (ZI nr. 15568865) Dimethylfumaraat Psorinovo tabletten MSR MVA 120 mg MH (ZI nr. 15568873). http://www.mierlohout.nl/engels/thepharmacy/index.html; http://www.amsterdamkliniek.com/treatments/pp/.html; http://www.efarma.nl/pages/iteminfo.asp?ItemID = 15568865 [cited 27 January 2014].
- National Italian register. Registro integratori elenco in ordine alfabetico per prodotto [updated 28 February 2013]. 797. Available from: http://www.salute.gov.it/imgs/C_17_pagineAree_1270_listaFile_itemName_6_file.pdf.
- Nextrasearch. Psocaps technical information sheet. Available from: http://www.nextrasearch.it/pdf/Technical_Psocaps.pdf [cited 16 January 2014].
- Australian Government, Department of Health. Pharmaceutical Benefit Scheme (PBS) – Dimethyl Fumarate. Available from: http://www.pbs.gov.au/medicine/item/2896K-2943X-2966D [cited 27 January 2014].
- Health Canada. Drugs & health products: Summary basis of decision – Tecfidera. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2013_tecfidera_154776-eng.php [cited 27 January 2014].
- Murteira S , Ghezaiel Z , Karray S , Lamure M . Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: Reassessment of nomenclature. JMAHP. 2013; 1: 21131.
- Murteira S, Millier A, Ghezaiel Z, Lamure M. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: Regulatory implications. JMAHP. 2014; 2: 22813. http://dx.doi.org/10.3402/jmahp.v2.22813.
- Murteira S, Millier A, Toumi M. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: Market access implications. JMAHP. 2014; 2: 22814. http://dx.doi.org/10.3402/jmahp.v2.22814.
- European Medicines Agency: Committee for Medicinal Products for Human Use. Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative, or a different salt or ester as new active substance in relation to the relevant reference active substance (EMA/651649/2010). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/11/WC500134993.pdf [cited 27 January 2014].
- Business Wire. CHMP determines dimethyl fumarate in TECFIDERA® to be a new active substance in the European Union. 22 November 2013. [Press release]. Available from: http://www.businesswire.com/news/home/20131122005436/en/CHMP-Determines-Dimethyl-Fumarate-TECFIDERA%C2%AE-Active-Substance#.UuXYILTTWpo [cited 27 January 2014].
- Sweetser MT , Dawson KT , Bozic C . Manufacturer's response to case reports of PML. N Engl J Med. 2013; 368(17): 1659–61.
- Schweckendiek W . Behandlung von Psoriasis mit lipoidloslichen fumarsaureverbindungen. Medizin Heute. 1966; 15: 219–20.
- Nieboer C , de Hoop D , Langendijk PN , van Loenen AC , Gubbels J . Fumaric acid therapy in psoriasis: A double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica. 1990; 181(1): 33–7.
- Nieboer C , de Hoop D , van Loenen AC , Langendijk PN , van Dijk E . Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasis. J Am Acad Dermatol. 1989; 20(4): 601–8.
- Pathirana D , Ormerod AD , Saiag P , Smith C , Spuls PI , Nast A et al. . European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009; 23(Suppl 2): 1–70.
- Moss A. Synthon advances copycat plans for MS drug Tecfidera with latest patent filing. Financial Times. 26 July 2013. Available from: http://www.ft.com/cms/s/2/d57ce7fa-f613–11e2-a55d-00144feabdc0.html [cited 27 January 2014].
- Global patent index – EP 2137537 B1. Compositions and uses for treating multiple sclerosis.
- Chancellor D. Multiple Sclerosis ∣ Market Forecast update. Datamonitor healthcare report. Available from: http://www.datamonitorhealthcare.com/multiple-sclerosis-market-forecast-update/ [cited 14 August 2013].
- Medtrack. Product Report, Tecfidera. 2013. Available from: https://oneview.medtrack.com [downloaded 26 January 2014].